Publication | Closed Access

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

UrologyGenitourinary CancerTherapy StratificationUrothelial CarcinomaMedicinePharmacologyImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentOncologyDrug Administration/ema-approvedTumor MicroenvironmentCancer Research